Irifrin BK drops 2.5% 0.4ml #15

Irifrin BK instruction

You can buy Irifrin BK here

See also - Irifrin

Composition

    In 1 ml of a 2.5% solution of eye drops contains:
    Active substance
    Phenylephrine hydrochloride is 25 mg.
    Excipients
    Disodium edetate 1.0 mg, sodium metabisulphite 2.0 mg, citric acid 1.16 mg, sodium citrate dihydrate. E., Hypromellose 3.0 mg, water for injection q.s.

Packaging

In a disposable tube of a dropper, 0.4 ml of a solution of drops of the eye. In a package of laminated paper 5 tubes of IV. In a pack of cardboard 3 bags of laminated paper.

pharmachologic effect of Irifrin BK

Adrenomimetic. It has a direct stimulating effect mainly on α-adrenergic receptors.
When systemic application causes a narrowing of arterioles, increases OPSS and blood pressure. Cardiac output does not change or decrease, which is associated with reflex bradycardia (increased vagal tone) in response to arterial hypertension. Phenylephrine raises blood pressure not as dramatically as norepinephrine and epinephrine, but it lasts longer. This, apparently, is due to the fact that phenylephrine is more stable and does not collapse under the influence of COMT.
With topical application phenylephrine has a pronounced vasoconstrictive effect, causes mydriasis, can lower the intraocular pressure with open-angle glaucoma.
In average therapeutic doses, it practically does not affect the central nervous system.

Pharmacokinetics

After ingestion, phenylephrine is poorly absorbed from the digestive tract. Metabolized with the participation of MAO in the intestinal wall and with the "first passage" through the liver. Bioavailability of phenylephrine is low.
After topical application, it undergoes systemic absorption.

Irifrin BK, indications for use

    Iridocyclitis (for the prevention of the appearance of posterior synechia and reduction of exudation from the iris).
    Expansion of the pupil in ophthalmoscopy and other diagnostic procedures necessary to monitor the state of the posterior segment of the eye, with laser interventions on the fundus and vitreoretinal surgery.
    Conducting a provocative test in patients with a narrow anterior chamber angle profile and suspicion of occlusive glaucoma.
    Differential diagnosis of superficial and deep injection of the eyeball.
    Syndrome of "red eye" (to reduce hyperemia and irritation of the mucous membrane of the eye).
    Prevention of asthenopia and spasm of accommodation in patients with high visual load.
    Treatment of false myopia (spasm of accommodation) and prophylaxis of the progres- sion of true myopia in patients with high visual load.

Contraindications for Irifrin BK

    Hypersensitivity to the components of Irifrin BK.
    Narrow-angle or angle-closure glaucoma.
    Arterial hypertension in combination with Ischemic heart disease aortic aneurysm, atrioventricular blockade of I - III degree, arrhythmia.
    Tachycardia.
    Diabetes mellitus type I in the anamnesis.
    Permanent intake of monoamine oxidase inhibitors, tricyclic antidepressants, antihypertensive drugs.
    Additional expansion of the pupil during surgical operations in patients with impaired integrity of the eyeball, as well as in violation of tear production.
    Reduced body weight in newborns.
    Hyperthyroidism.
    Hepatic porphyria.
    Congenital deficiency of glucose-6-phosphate dehydrogenase.
    The period of breastfeeding.

Carefully:

    In patients with type II diabetes - an increased risk of increasing blood pressure.
    In elderly patients - increased risk of reactive miosis.
    Exceeding the recommended dose of 2.5% solution in patients with trauma, eye disease or its appendages, in the postoperative period, or with reduced tear production can lead to an increase in the absorption of phenylephrine and the development of systemic side effects.
    Because of what causes conjunctival hypoxia - in patients with sickle cell anemia, with contact lenses, after surgical interventions (decreased healing).
    At a cerebral atherosclerosis.
    With long-term bronchial asthma.

Dosing and Administration

When conducting ophthalmoscopy, single instillations of 2.5% Irifrin BK solution are used. As a rule, to create mydriasis, it is enough to administer 1 drop of 2.5% solution of Irifrin BK into the conjunctival sac.
Maximum Mydriaz is reached after 15-30 minutes and remains at a sufficient level for 1-3 hours. If it is necessary to maintain mydriasis for a long time, after 1 hour, the repeated instillation of Irifrin BK is possible.
For diagnostic procedures:
    As a provocative test, patients with a narrow anterior chamber angle profile and suspicion of occlusive glaucoma are instilled with 1 drop of Irifrin BK once. If the difference between the values ​​of intraocular pressure before instillation of IrifrinavBK and after dilating the pupil is from 3 to 5 mm Hg. the provocative test is considered positive.
    For differential diagnosis injection type eyeball dug 1 drop of the preparation once if 5 minutes after instillation indicated vasoconstriction eyeball, the injection is classified as surface while maintaining redness eyes must carefully examine the patient for the presence iridocyclitis or scleritis, since it indicates expansion of deeper lying vessels.
With iridocyclites
    To prevent the development and breaking the already formed posterior synechiae and to reduce exudation into the anterior chamber 1 drop preparation is dug into the conjunctival sac of the patient eye 2-3 times a day 5-10 days depending on the severity of the disease.
At schoolboys
    With myopia of weak degree
    For the prevention of spasm of accommodation in the period of high visual load 1 drop Irifrin BC is buried in the evening before bedtime.
    With progressive myopia of medium degree
    3 times a week in the evening before bedtime.
    With emmetropia
    In the daytime, depending on the load.
At a hypermetropia with a tendency to a spasm of accommodation at a high visual load
    Bury in the evening Irifrin BC in combination with a 1% solution of cyclopentolate. Irritin BK is instilled in the usual visual load 3 times a week in the evening before going to sleep.
In the treatment of false and true myopia
    One drop of Irifrin BC is applied in the evening before bedtime 2-3 times a week for a month.

Application in pregnancy and lactation

Pregnancy

In animals late in pregnancy, phenylephrine caused a delay in fetal growth and stimulated early onset of labor.
The effect of irifrin BC in pregnant women is not well understood, therefore, the use of the drug in this category of patients should only be if the expected benefit for the mother exceeds the risk of developing possible side effects for the fetus.

Lactation

In the case of the appointment of Irifrin BK in lactation, breast-feeding should be discontinued.

Side effects of Irifrin BK

Local
Conjunctivitis, keratitis, periorbital edema, eye pain, burning during instillation, lacrimation, blurred vision, irritation, discomfort, increased intraocular pressure, blocking the anterior chamber angle (angle at the narrowing), allergic reactions, reactive hyperemia. Phenylephrine may cause a reactive miosis the next day after application. Repeated instillations of the drug at this time may give a less pronounced Midriaz than the day before. This effect is more common in elderly patients. Due to the significant reduction of pupil dilator exposed to phenylephrine in 30-45 minutes after instillation in the anterior chamber humidity may be detected by the pigment particles from the pigment leaf of the iris, a slurry of chamber moisture is necessary to differentiate the manifestations anterior uveitis or to exposure of blood cells in the anterior chamber of moisture .
System
Contact dermatitis.
From the side of the cardiovascular system
Rapid heart rate, tachycardia, arrhythmia, increased blood pressure, ventricular arrhythmia, reflex bradycardia, coronary artery occlusion, pulmonary embolism.

Drug Interactions

The mydriatic effect of phenylephrine is enhanced when used in combination with topical application of atropine. Because of the increased vasopressor effect, tachycardia can develop.
Application Irifrin BK for 21 days after discontinuation of patients monoamine oxidase inhibitors, and tricyclic antidepressants must be administered with caution, because in this case there is an uncontrolled rise in blood pressure.
Pressor effect of adrenergic agents may also be potentiated when combined with tricyclic antidepressants, beta-blockers, reserpine, guanethidine, methyldopa and m-holinoblokatorami.
Irifrin BK can potentiate the inhibition of cardiovascular activity with inhalation anesthesia as a result of increased myocardial sensitivity to sympathomimetics and the occurrence of ventricular fibrillation.
The use together with other sympathomimetics can increase the cardiovascular effects of phenylephrine.
The use of phenylephrine can cause a weakening of concomitant antihypertensive therapy and lead to an increase in the level of arterial pressure, tachycardia.
Pre-instillation of local anesthetics can increase systemic absorption and prolong the Midriaz.

Overdose with Irifrin BK

Symptoms: Overdosage is anxiety, nervousness, dizziness, sweating, vomiting, rapid heartbeat, weak or shallow breathing.
Treatment: when a systemic effect of phenylephrine occurs, it is possible to quench unwanted effects by, using alpha-adrenergic blocking agents, for example, 5 to 10 mg of phentolamine intravenously. If necessary, the injection can be repeated.

Storage conditions

At room temperature (up to 25 ° C) in a place protected from light and inaccessible to children. Do not freeze.

Terms of sell

To buy Irifrin BK you don't need a prescription.